Product Data Sheet

(R)-OY-101

Cat. No.: HY-149053B CAS No.: 23495-82-1 Molecular Formula: $C_{27}H_{31}NO_{4}$

Molecular Weight: 433.54

Target: P-glycoprotein; Apoptosis

Administration

manner

Pathway: Membrane Transporter/Ion Channel; Apoptosis

Please store the product under the recommended conditions in the Certificate of Storage:

Analysis.

BIOLOGICAL ACTIVITY

Description (R)-OY-101 is an orally active and specific inhibitor of P-gp. (R)-OY-101 increases tumor sensitivity to anticancer agents. (R)-OY-101 has good activity tumor resistance and promoting apoptosis and can be used in cancer related research [1].

In Vitro (R)-OY-101 increases the cytotoxicity of Vincristine (HY-N0488A) on Eca109/VCR cells with an IC50 value of 9.9 nM^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo Pharmacokinetic (PK) parameters of OY-101 in SD Rats^[1]

Notes: (R)-OY-101 is a stereoscopic configuration of OY-101.

 T_{max} (h) C_{max} (ng/mL) λ_z (1/h) $T_{1/2}$ (h)

Intravenous $0.17 \pm 0.121573.20 \pm 143.970.15 \pm 0.138.43 \pm 7.832.68 \pm 0.472688.45 \pm 180.102742.45 \pm 218.99\ 7391.35 \pm 1874.05\ 12.84 \pm 11.33\ 1.10 \pm 0.121573.20 \pm 143.970.15 \pm 0.138.43 \pm 7.832.68 \pm 0.472688.45 \pm 180.102742.45 \pm 218.99\ 7391.35 \pm 1874.05\ 12.84 \pm 11.33\ 1.10 \pm 0.121573.20 \pm 143.970.15 \pm 0.138.43 \pm 7.832.68 \pm 0.472688.45 \pm 180.102742.45 \pm 218.99\ 7391.35 \pm 1874.05\ 12.84 \pm 11.33\ 1.10 \pm 0.121573.20 \pm 143.970.15 \pm 0.138.43 \pm 7.832.68 \pm 0.472688.45 \pm 180.102742.45 \pm 218.99\ 7391.35 \pm 1874.05\ 12.84 \pm 11.33\ 1.10 \pm 0.121573.20 \pm 1.01010.10 \pm 0.121573.20 \pm 0.138.43 \pm 0.1010.10 \pm 0.121573.20 \pm 0.138.43 \pm 0.1010.10 \pm 0.1010.1$ injection

 MRT_{0-inf}

AUC_{0-t} (ng

/mL•h)

AUC_{0-inf} (ng

/mL•h)

AUMC_{0-inf} (ng

 $/mL \cdot h^2$)

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Zeng R, et al. Simplified Derivatives of Tetrandrine as Potent and Specific P-gp Inhibitors to Reverse Multidrug Resistance in Cancer Chemotherapy. J Med Chem. 2023 Mar 23;66(6):4086-4105.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Screening Libraries

Inhibitors

Proteins

(L/kg/

 V_7/F (L/kg)